Plenary Talk: Nano-biotechnology: Omega-3 Oils and Nanofibres @ Sathyam Hall
Aug 12 @ 1:30 pm – 2:05 pm

collinColin Barrow, Ph.D.
Chair in Biotechnology, School of Life & Environmental Sciences, Deakin University, Australia

Nano-biotechnology: Omega-3 Oils and Nanofibres

The health benefits of long-chain omega-3 fatty acids are well established, especially for eicosapentaenoic acid (EPA) and docosapentaenoic acid (DHA) from fish and microbial sources. In fact, a billion dollar market exists for these compounds as nutritional supplements, functional foods and pharmaceuticals. This presentation will describe some aspects of our omega-3 biotechnology research that are at the intersection of Nano-biotechnology and oil chemistry. These include the use of lipases for the concentration of omega-3 fats, through immobilization of these lipases on nanoparticles, and the microencapsulation and stabilization of omega-3 oils for functional foods. I will also describe some of our work on the enzymatic production of resolvins using lipoxygenases, and the fermentation of omega-3 oils from marine micro-organisms. Finally, I will describe some of our work on the formation of amyloid fibrils and graphene for various applications in nano-biotechnology.


Invited Talk: Nanoscale Simulations – Tackling Form and Formulation Challenges in Drug Development and Drug Delivery @ Sathyam Hall
Aug 13 @ 2:15 pm – 2:40 pm

lalithaLalitha Subramanian, Ph.D.
Chief Scientific Officer & VP, Services at Scienomics, USA

Nanoscale Simulations – Tackling Form and Formulation Challenges in Drug Development and Drug Delivery

Lalitha Subramanian, Dora Spyriouni, Andreas Bick, Sabine Schweizer, and Xenophon Krokidis Scienomics

The discovery of a compound which is potent in activity against a target is a major milestone in Pharmaceutical and Biotech industry. However, a potent compound is only effective as a therapeutic agent when it can be administered such that the optimal quantity is transported to the site of action at an optimal rate. The active pharmaceutical ingredient (API) has to be tested for its physicochemical properties before the appropriate dosage form and formulation can be designed. Some of the commonly evaluated parameters are crystal forms and polymorphs, solubility, dissolution behavior, stability, partition coefficient, water sorption behavior, surface properties, particle size and shape, etc. Pharmaceutical development teams face the challenge of quickly and efficiently determining a number of properties with small quantities of the expensive candidate compounds. Recently the trend has been to screen these properties as early as possible and often the candidate compounds are not available in sufficient quantities. Increasingly, these teams are leveraging nanoscale simulations similar to those employed by drug discovery teams for several decades. Nanoscale simulations are used to predict the behavior using very little experimental data and only if this is promising further experiments are done. Another aspect where nanoscale simulations are being used in drug development and drug delivery is to get insights into the behavior of the system so that process failures can be remediated and formulation performance can be improved. Thus, the predictive screening and the in-depth understanding leads to experimental efficiency resulting in far-reaching business impacts.

With specific examples, this talk will focus on the different types of nanoscale simulations used to predict properties of the API in excipients and also provide insight into system behavior as a function of shelf life, temperature, mechanical stress, etc.